Assuntos
Aterosclerose/terapia , Colesterol/sangue , Dislipidemias/terapia , Adolescente , Adulto , Idoso , Aterosclerose/prevenção & controle , Biomarcadores/sangue , Doenças Cardiovasculares/etiologia , Criança , Ésteres do Colesterol/sangue , Dislipidemias/sangue , Dislipidemias/prevenção & controle , Ácidos Graxos/metabolismo , Feminino , Ácidos Fíbricos/metabolismo , Humanos , Hipercolesterolemia/sangue , Hipertrigliceridemia/sangue , Expectativa de Vida , Lipoproteínas/metabolismo , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Triglicerídeos/sangueAssuntos
Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Aterosclerose/terapia , Colesterol/sangue , Dislipidemias/terapia , Aterosclerose/prevenção & controle , Biomarcadores/sangue , Doenças Cardiovasculares/etiologia , Ésteres do Colesterol/sangue , Dislipidemias/sangue , Dislipidemias/prevenção & controle , Ácidos Graxos/metabolismo , Ácidos Fíbricos/metabolismo , Hipercolesterolemia/sangue , Hipertrigliceridemia/sangue , Expectativa de Vida , Lipoproteínas/metabolismo , Fatores de Risco , Triglicerídeos/sangueAssuntos
Doenças Cardiovasculares/prevenção & controle , Gorduras na Dieta/efeitos adversos , Aterosclerose/etiologia , Aterosclerose/prevenção & controle , Biomarcadores/sangue , Doenças Cardiovasculares/etiologia , Gorduras na Dieta/administração & dosagem , Medicina Baseada em Evidências , Humanos , Fatores de RiscoAssuntos
Humanos , Doenças Cardiovasculares/prevenção & controle , Gorduras na Dieta/efeitos adversos , Aterosclerose/etiologia , Aterosclerose/prevenção & controle , Biomarcadores/sangue , Doenças Cardiovasculares/etiologia , Gorduras na Dieta/administração & dosagem , Medicina Baseada em Evidências , Fatores de RiscoAssuntos
Doenças Cardiovasculares/prevenção & controle , Promoção da Saúde , Aspirina/uso terapêutico , Brasil , Medicina Baseada em Evidências , Feminino , Humanos , Hipertensão/prevenção & controle , Metanálise como Assunto , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Fatores de Risco , Resultado do TratamentoAssuntos
Hiperlipoproteinemia Tipo II/diagnóstico , Hiperlipoproteinemia Tipo II/terapia , Brasil , Doenças Cardiovasculares/etiologia , Humanos , Hiperlipoproteinemia Tipo II/genética , Hiperlipoproteinemia Tipo II/mortalidade , Metabolismo dos Lipídeos/fisiologia , Necessidades Nutricionais , Fatores de RiscoRESUMO
BACKGROUND: Oxidative stress plays an important role in the pathophysiology of diabetes mellitus. The aim of this study was to evaluate the formation of cholesterol oxides (ChOx) as biomarkers of oxidative stress in subjects with impaired glucose tolerance (IGT) and diabetes. METHODS: Blood plasma levels of cholesterol oxidation products were determined in the following groups: type 1 diabetes mellitus (DM1), type 2 diabetes (DM2), impaired glucose tolerance (IGT), children without diabetes (C1) and adults without diabetes (C2). The serum levels of cholest-5-ene-3alpha,7alpha-diol (7alpha-hydroxycholesterol, 7alpha-OH), cholest-5-ene-3beta,7beta-diol (7beta-hydroxycholesterol, 7beta-OH), 3beta-hydroxycholest-5-7-one (7-ketocholesterol, 7-K), 5alpha-cholestane-3beta,5,6beta-triol (cholestanetriol), 5,6alpha-epoxy-5alpha-cholestan-3alpha-ol (cholesterol-5alpha,6alpha-epoxide,), 5,6beta-epoxy-5beta-cholestan-3beta-ol (cholesterol-5beta,6beta-epoxide) and cholest-5-eno-3beta,25-diol (25-hydroxycholesterol, 25-OH) (trivial name and abbreviations indicated in parentheses) were quantified by gas chromatography using flame ionization detection. RESULTS: The levels of total ChOx were elevated in the DM1 and DM2 groups compared to age-matched subjects without diabetes (p < 0.05). The concentrations of 7beta-hydroxycholesterol, cholesterol-alpha-epoxide and cholesterol-beta-epoxide were higher in the blood plasma of subjects in the DM2 group than in the blood plasma of subjects in the C2 and IGT groups (p < 0.05). Treatment of type 2 diabetic patients with oral hypoglycemic drugs associated with insulin resulted in lower concentrations of nitrotyrosine in the blood plasma without significant changes in the concentrations of glucose and glycated hemoglobin. Moreover, combination with statins in both treatments decreased the concentrations of ChOx. CONCLUSIONS: ChOx are suitable biomarkers of oxidative stress and may be useful in clinical studies to follow drug effects on lipid oxidative modifications in diabetic patients.
Assuntos
Colesterol/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Estresse Oxidativo/fisiologia , Adolescente , Adulto , Idoso , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Biomarcadores , Criança , Colestanóis/sangue , Colesterol/análogos & derivados , Colesterol/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Feminino , Intolerância à Glucose/sangue , Humanos , Hidroxicolesteróis/sangue , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Cetocolesteróis/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
Background Oxidative stress plays an important role in the pathophysiology of diabetes mellitus. The aim of this study was to evaluate the formation of cholesterol oxides (ChOx) as biomarkers of oxidative stress in subjects with impaired glucose tolerance (IGT) and diabetes. Methods Blood plasma levels of cholesterol oxidation products were determined in the following groups: type 1 diabetes mellitus (DM1), type 2 diabetes (DM2), impaired glucose tolerance (IGT), children without diabetes (C1) and adults without diabetes (C2). The serum levels of cholest-5-ene-3£/,7£/-diol (7£/-hydroxycholesterol, 7£/-OH), cholest- 5-ene-3£],7£]-diol (7£]-hydroxycholesterol, 7£]-OH), 3£]-hydroxycholest-5-7- one (7-ketocholesterol, 7-K), 5£/-cholestane-3£],5,6£]-triol (cholestanetriol), 5,6£/-epoxy-5£/-cholestan-3£/-ol (cholesterol-5£/,6£/-epoxide,), 5,6£]-epoxy- 5£]-cholestan-3£]-ol (cholesterol-5£],6£]-epoxide) and cholest-5-eno-3£],25-diol (25-hydroxycholesterol, 25-OH) (trivial name and abbreviations indicated in parentheses) were quantified by gas chromatography using flame ionization detection. Results The levels of total ChOx were elevated in the DM1 and DM2 groups compared to age-matched subjects without diabetes (p < 0.05).The concentrations of 7£]-hydroxycholesterol, cholesterol-£/-epoxide and cholesterol-£]-epoxide were higher in the blood plasma of subjects in the DM2 group than in the blood plasma of subjects in the C2 and IGT groups (p < 0.05). Treatment of type 2 diabetic patients with oral hypoglycemic drugs associated with insulin resulted in lower concentrations of nitrotyrosine in the blood plasma without significant changes in the concentrations of glucose and glycated hemoglobin. Moreover, combination with statins in both treatments decreased the concentrations of ChOx.Conclusions ChOx are suitable biomarkers of oxidative stress and may be useful in clinical studies to follow drug effects on lipid oxidative modifications in diabetic patients. Copyright ÆÉ 2006 John Wiley & Sons, Ltd.
